$2.31
-0.13-5.12%
Last update: Nov 10, 1:41 PM
AC Immune SA
ACIUNASDAQ
AC Immune fell 27.2% from $3.35 to $2.44, behind the S&P 500's +10.5%. Its worst day was Dec 17 (−10.6%), and its low came Nov 2 at $2.06.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
AC Immune shares rose 15.4%, while the S&P 500 rose 0.2%.
+15.4%, the year's best day, on 20M shares, the year's heaviest volume · S&P 500 +0.2%
Story events cover the past 12 months · Times ET
AC Immune closed at its highest level of the year, 10.4% above where the year started.
+5.1% · S&P 500 −0.2%
EPS of $-0.17 beat the $-0.19 estimate on $422,914.00 revenue (est. $2.3M).
+0.5% · S&P 500 −0.6%
Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment.
+15.2% · S&P 500 0.0%
EPS of $-0.19 beat the $-0.20 estimate on $1.4M revenue (est. $1.0M).
+3.4% · S&P 500 +1.0%
AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced interim data from the first three cohorts (AD1, AD2 & AD3) of
−10.5% · S&P 500 +0.8%
EPS of $0.03 beat the $-0.22 estimate on $19.1M revenue (est. $1.0M).
+0.9% · S&P 500 −0.2%
EPS of $-0.16 beat the $-0.22 estimate on $4.0M revenue (est. $1.0M).
+9.6% · S&P 500 +1.7%
Where it ended: a close of $2.44 on Nov 9, 2026.
Nothing in the past 12 months.
All ACIU analyst actionsNothing in the past 12 months.
All ACIU dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ACIU and SPY from Benzinga historical bars. Not investment advice.
